Beneficial effect of mioflazine in limiting myocardial infarct size in the anesthetized dog.
The effect of mioflazine (R 51 469) on infarct size was studied in anesthetized dogs subjected to 24 h of LAD (left anterior descending) coronary artery occlusion. The myocardium normally supplied by the occluded coronary artery (perfusion area, PA) was delineated by perfusion of the arterial bed distal to the occlusion with colorless fluid while the remainder of the heart was simultaneously perfused with an Evans blue solution. After sectioning the heart, infarct areas (IA) could be visualized by incubation of the slices in triphenyl-tetrazolium-chloride (TTC). Quantification of the areas was performed using a Quantimet 900 image analysis system. The animals either received mioflazine (2.5 mg X kg-1 orally) or a same volume of 20% polypropylene glycol, the solvent of mioflazine 2.5 h before the start of the surgical procedure. For perfusion areas greater than 20% of the left ventricle infarct size was significantly reduced in mioflazine pretreated animals compared with the control group, both expressed as per cent of the left ventricle (10.6 +/- 2.3 vs 19.2 +/- 1.5, p less than 0.005) and as per cent of the perfusion area (35.1 +/- 7 vs 64.4 +/- 5, p less than 0.005).
D000758:Anesthesia; D000818:Animals; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004285:Dogs; D005260:Female; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D010879:Piperazines / Q000494:pharmacology*
D002317:Cardiovascular Agents; D010879:Piperazines; C041518:mioflazine